微芯生物(688321.SH):主要產品西達本胺續約進入國家醫保目錄
格隆匯11月28日丨微芯生物(688321.SH)公佈,根據國家醫保局、人力資源社會保障部印發的關於《國家基本醫療保險、工傷保險和生育保險藥品目錄》的通知(醫保發[2019]46號),公司主要產品西達本胺續約進入國家醫保目錄。該產品具體情況如下:
藥品名稱:西達本胺
註冊類別:化學藥品第1.1類
藥品分類:抗腫瘤藥及免疫調節劑-其他抗腫瘤藥物
醫保分類:乙類
編號:71
劑型:口服常釋劑型
獨家品種:是
醫保支付標準:343元(5mg/片)
功能主治:限既往至少接受過一次全身化療的復發或難治的外周T細胞淋巴瘤(PTCL)患者
協議有效期:2020年1月1日至2021年12月31日
公司產品西達本胺已於2017年7月進入國家醫保目錄,本次續約進入國家醫保目錄將有利於該產品的銷售,對公司的經營發展有積極的作用,預計短期不會對公司業績產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.